Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.68 |
| ▸ | THRB | P10828 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.63 |
| ▸ | SLC6A5 | Q9Y345 | 7/20 | 0.62 |
| ▸ | SLC6A9 | P48067 | 6/20 | 0.61 |
| ▸ | GPR174 | Q9BXC1 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | DPP4 | P27487 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30957484 | 1.00 | LMNA (0.69) | LMNAMAPTTHRBALDH1A1POLB | |
| SCHEMBL1498664 | 0.88 | POLB (0.65) | LMNAMAPTTHRBALDH1A1POLB | |
| SCHEMBL14464189 | 0.87 | ALDH1A1 (0.79) | LMNAMAPTTHRBALDH1A1POLB | |
| SCHEMBL5240376 | 0.86 | ALDH1A1 (0.65) | LMNAMAPTTHRBALDH1A1KMT2A | |
| SCHEMBL3216259 | 0.86 | LMNA (0.64) | LMNAMAPTTHRBALDH1A1POLB | |
| SCHEMBL1985188 | 0.86 | MAPT (0.61) | LMNAMAPTTHRBALDH1A1POLB | |
| SCHEMBL3542256 | 0.85 | LMNA (0.70) | LMNAMAPTTHRBALDH1A1KMT2A | |
| SCHEMBL3547962 | 0.85 | ALDH1A1 (0.74) | LMNAMAPTALDH1A1KMT2AMEN1 | |
| SCHEMBL28702263 | 0.84 | MAPT (0.70) | LMNAMAPTTHRBALDH1A1POLB | |
| SCHEMBL994347 | 0.84 | ALDH1A1 (0.68) | LMNAMAPTTHRBALDH1A1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023287783-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | ACEA Therapeutics, Inc. (US) | 2023-01-19 | — | — | WO | disclosed |
| US-7671058-B2 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-03-02 | — | — | US | disclosed |
| US-7655652-B2 | 2-{4-[4-(2-hydroxyacetyl)piperazin-1-yl]anilino}-4-(1-isopropyl-2-methyl-1H-imidazol-5-yl)-5-fluoropyrimidine hydrochloride; cell cycle inhibitory; rheumatoid arthritis | ASTRAZENECA AB (SE) | 2010-02-02 | — | — | US | disclosed |
| CN-100528865-C | Imidazolo-5-yl-anilinopyrimidines as agents for the inhibition of cell proliferation | ASTRAZENECA AB (SE) | 2009-08-19 | — | — | CN | disclosed |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20070161615-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2007-07-12 | — | — | US | disclosed |
| CN-1938295-A | Imidazol-5-yl-anilinopyrimidines as cell proliferation inhibitors | ASTRAZENECA AB (SE) | 2007-03-28 | — | — | CN | disclosed |
| EP-1748999-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | AstraZeneca AB (SE) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005075461-A1 | IMIDAZOLO-5-YL-2-ANILINOPYRIMIDINES AS AGENTS FOR THE INHIBITION OF CELL PROLIFERATION | ASTRAZENECA AB (SE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161615-A1 | Chemical compounds | MKI67, PCNA, CCNI | LMNA 988/4885MAPT 3632/4885THRB 3973/4885 |
| US-20080227784-A1 | N-(3,4-disubstituted phenyl) salicylamide derivatives | STAT6, RELA, NFKB2 | LMNA 2990/4885MAPT 4713/4885THRB 1171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.